Study of the safety of SGLT-2 inhibitors for heart failure patients with type 2 diabetes mellitus
Not Applicable
- Conditions
- heart failure patients with type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000018996
- Lead Sponsor
- ippon Medical School Department of Cardiovascular Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Type 1 diabetes 2) With severe renal dysfunction (eGRF <30 mL/min or patient undergoing artificial dialysis) 3) Heart failure patient whose NYHA functional classification is IV 4) SGLT-2 inhibitor has been administered from admission to registration 5) Physicians and other staff have been deemed inappropriate for registration of this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The usage dose of loop, thiazides diuretics and tolvaptan at 4 weeks and 24 weeks.
- Secondary Outcome Measures
Name Time Method